Founded in 2020, Modus QA develops phantoms used to perform quality assurance (QA) for radiation therapy. For IBA, the acquisition will benefit its dosimetry operations in North America and add complementary phantom products to its radiation therapy QA portfolio, according to the vendor. IBA said it would market Modus QA's products to its large client base and expand the reach of the products to new markets in Europe and Asia.
Furthermore, the companies will collaborate to expand their medical imaging and proton therapy product portfolio and grow existing OEM relationships. With the goal of offering a full range of QA products to proton therapy centers, IBA will also utilize Modus QA's experience to develop new dosimetry products for proton therapy applications, the firms said.
All Modus employees have joined IBA.
Copyright © 2022 AuntMinnie.com